TRANSVERSE MYELITIS ON THE BACKGROUND OF HEPATITIS C RESPONDING TO TREATMENT OF THE VIRUS – A CASE REPORT

Tattoos have become increasingly popular worldwide making adverse effects from tattoos a growing concern. In our report, we present a 51-year-old man who developed an unusual allergic reaction to the red ink portions of his tattoos that coincided with the initiation of ledipasvir/sofosbuvir treatment for his hepatitis C. Clinical and histological features were consistent with a delayed-type hypersensitivity reaction to red ink.

Download Full-text

Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection

American Journal of Health-System Pharmacy ◽

10.1093/ajhp/zxaa328 ◽

2020 ◽

Vol 78 (1) ◽

pp. 36-40

Author(s):

Vanessa Huffman ◽

Diana C Andrade ◽

Elizabeth Sherman ◽

Jianli Niu ◽

Paula A Eckardt

Keyword(s):

Case Report ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Percutaneous Endoscopic Gastrostomy ◽

Fixed Dose ◽

Pharmacokinetic Data ◽

Percutaneous Endoscopic Gastrostomy Tube ◽

Endoscopic Gastrostomy ◽

Hiv Coinfection ◽

Peg Tube

Abstract Purpose Ledipasvir/sofosbuvir is an oral combination therapy containing fixed doses of direct-acting antiviral agents indicated for the treatment of hepatitis C virus (HCV) infection. Currently there are limited data on the clinical efficacy of crushed ledipasvir/sofosbuvir administered via feeding tube. Summary This case report discusses the successful treatment of chronic HCV genotype 1b infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy (PEG) tube in a patient with human immunodeficiency virus (HIV) coinfection and high-grade sarcoma who had severe swallowing difficulties. The patient received crushed ledipasvir/sofosbuvir daily for a total of 12 weeks. At 12 weeks the patient had achieved a sustained virologic response. Conclusion Currently, ledipasvir/sofosbuvir is available only as a tablet, with limited pharmacokinetic data available to guide clinicians on use of the fixed-dose combination medication in crushed form. This case report highlights our experience treating a patient with HCV/HIV coinfection through administration of crushed ledipasvir/sofosbuvir via PEG tube, which we found to be a safe and effective therapeutic option.

Download Full-text

Idenix v. Gilead: The enablement and written description limits of a genus claim

Journal of Generic Medicines The Business Journal for the Generic Medicines Sector ◽

10.1177/17411343211013572 ◽

2021 ◽

Vol 17 (2) ◽

pp. 77-83

Author(s):

Keith A Zullow ◽

Cindy Chang ◽

Sean Anderson

Keyword(s):

Case Report ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Supreme Court ◽

The Supreme Court ◽

Federal Circuit ◽

Written Description ◽

Insufficient Number

In Idenix Pharms. LLC v. Gilead Sci. Inc., 941 F.3d 1149 (Fed. Cir. 2019), the Federal Circuit affirmed a judgment of invalidity of a patent claiming methods for treating Hepatitis C virus for, inter alia, lack of enablement. The Supreme Court denied Idenix’s petition for a writ of certiorari, meaning that the Federal Circuit decision stands, and genus claims covering thousands of compounds that were supported by an insufficient number of examples have failed the enablement test not once, but twice. See Wyeth & Cordis Corp. v. Abbott Labs., 720 F.3d 1380 (Fed. Cir. 2013). This case report presents the context surrounding the Federal Circuit’s Idenix decision and the Supreme Court’s decision not to hear the case.

Download Full-text